Sinopharm Group Co. Ltd.
SHTDFOTCHealthcare● Active
$2.30
+$0.01(+0.44%)
Market Cap$7.2B
P/E Ratio—
52W High$2.7
52W Low$2.11
Sinopharm Group Co. Ltd. (SHTDF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SHTDF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $560.33B | $584.51B | $596.57B | $552.15B | $521.05B |
| Cost of Revenue | $520.17B | $540.25B | $548.06B | $504.71B | $477.00B |
| Gross Profit | $40.15B | $44.26B | $48.51B | $47.43B | $44.05B |
| Gross Margin %(computed) | 7.17% | 7.57% | 8.13% | 8.59% | 8.45% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $8.41B | $8.68B | $8.18B | $7.76B |
| Total Operating Expenses | $23.92B | $28.07B | $28.30B | $26.83B | $24.34B |
| Operating Income | $16.24B | $16.19B | $20.21B | $20.60B | $19.71B |
| Operating Margin %(computed) | 2.90% | 2.77% | 3.39% | 3.73% | 3.78% |
| Interest Income | $0.49B | $0.62B | $0.53B | $0.54B | $0.56B |
| Interest Expense | $2.43B | $2.73B | $2.96B | $3.52B | $3.76B |
| Income Before Tax | $14.42B | $14.00B | $19.51B | $18.56B | $17.00B |
| Income Tax Expense | $3.86B | $3.58B | $4.50B | $4.22B | $3.94B |
| Net Income | $6.97B | $7.05B | $9.05B | $8.53B | $7.76B |
| Net Margin %(computed) | 1.24% | 1.21% | 1.52% | 1.54% | 1.49% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.24 | $2.26 | $2.90 | $2.73 | $2.49 |
| Wtd Avg Shares | 3.12B | 3.12B | 3.12B | 3.12B | 3.11B |
| EBITDA | $20.41B | $20.17B | $26.90B | $26.25B | $24.68B |
| EBITDA Margin %(computed) | 3.64% | 3.45% | 4.51% | 4.75% | 4.74% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CNY · B
Explore more Sinopharm Group Co. Ltd. data
About Sinopharm Group Co. Ltd. (SHTDF) Income Statement
Sinopharm Group Co. Ltd. (SHTDF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, SHTDF reported revenue of $560.33B, gross profit of $40.15B (gross margin 7.17%), and net income of $6.97B — a net profit margin of 1.24%.
Frequently asked questions
SHTDF · 4 questionsSinopharm Group Co. Ltd. (SHTDF) reported revenue of $560.33B for 2025, down 4.1% year-over-year.
SHTDF revenueSHTDF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09